Neuronal voltage-gated sodium channel (Nav1.x)

Neuronal voltage-gated sodium channels (Nav1.x) are a family of transmembrane proteins, including subtypes Nav1.1, 1.2, 1.3, 1.6, 1.7, 1.8, and 1.9, that are essential for the initiation and propagation of action potentials in the central and peripheral nervous systems [1, 14]. These channels consist of a large, pore-forming alpha subunit and associated auxiliary beta subunits that modulate channel kinetics, trafficking, and cell adhesion [12, 19]. Upon membrane depolarization, the channels open to allow a rapid influx of sodium ions, which further depolarizes the cell and triggers electrical signaling [8, 13]. Mutations in the genes encoding these channels (SCN family) are linked to a variety of "channelopathies," including various forms of epilepsy, chronic and neuropathic pain syndromes, and neurodevelopmental disorders [2, 13, 17]. Pharmacologically, they are the primary targets for local anesthetics, anti-epileptics, and certain analgesics, which typically act by binding to the inner pore and stabilizing the inactivated state to suppress pathological neuronal hyperexcitability [1, 3, 4]. Modern drug discovery efforts focus on developing subtype-selective inhibitors to minimize off-target effects, such as cardiotoxicity from Nav1.5 inhibition or central nervous system side effects from non-selective blockade [4, 6]. These channels also serve as the primary targets for various natural neurotoxins, such as tetrodotoxin and saxitoxin, which have been instrumental in mapping the channel's structural and functional domains [15, 16].

Other names

Voltage-gated sodium channelNav channelSCN familySodium channel protein type alpha subunitNeuronal sodium channel

Pore blockade of the alpha subunit to inhibit sodium ion influx, stabilizing the inactive state of the channel and reducing neuronal firing frequency.